UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Library Location
Language
Publication DateJournal of clinical oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2490 - 2498
AP26113 | POTENT | ALK INHIBITORS | SAFETY | CERITINIB | BRAIN METASTASES | RESISTANCE | OPEN-LABEL | CHEMOTHERAPY | PROGRESSION | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Young Adult | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Headache - chemically induced | Pyridines - therapeutic use | Crizotinib | Organophosphorus Compounds - adverse effects | Cough - chemically induced | Pyrimidines - administration & dosage | Organophosphorus Compounds - therapeutic use | Treatment Outcome | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Retreatment | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Aged | Organophosphorus Compounds - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Details 
Digital rights
Loading RightsBritish journal of haematology, ISSN 0007-1048, 01/2021, Volume 192, Issue 1, pp. e17 - e21
Journal Article
Details
Digital rights
Loading RightsCancer, ISSN 0008-543X, 04/2013, Volume 119, Issue 8, pp. 1467 - 1477
fluorescence in situ hybridization | non–small cell lung cancer | crizotinib | gene rearrangements | anaplastic lymphoma kinase (ALK) | non-small cell lung cancer | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - enzymology | Lung Neoplasms - diagnosis | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Crizotinib | Dosage and administration | Genetic engineering | Genetic aspects | Research | Diagnosis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Phosphotransferases | Index Medicus | Abridged Index Medicus | anaplastic lymphoma kinase (ALK) gene rearrangements
Journal Article
Details
Digital rights
Loading RightsBiochemical journal, ISSN 0264-6021, 06/2009, Volume 420, Issue 3, pp. 345 - 361
Extracellular-signal-regulated kinase (ERK) | Pleiotrophin | Anaplastic large cell lymphoma (ALCL) | Neuroblastoma | Non-small cell lung cancer (NSLCL) | Midkine | Anaplastic lymphoma kinase (ALK) | Inflammatory myofibroblastic tumour (IMT) | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Oncogene Proteins, Fusion - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Neuroblastoma - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung Neoplasms - pathology | Nuclear Proteins - metabolism | Receptor Protein-Tyrosine Kinases | Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Neuroblastoma - metabolism | Nuclear Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - metabolism | Neuroblastoma - pathology | Lymphoma, Large-Cell, Anaplastic - genetics | Index Medicus | ALK, anaplastic lymphoma kinase | LTK, leucocyte tyrosine kinase | MUC-1, mucin-1 | IRS-1, IR substrate-1 | PTN, pleiotrophin | TGFβ, transforming growth factor β | neuroblastoma | extracellular-signal-regulated kinase (ERK) | pleiotrophin | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | Shc, Src homology and collagen homology | TPM, tropomyosin | IMP cyclohydrolase | MK, midkine | MYH9, non-muscle myosin heavy chain | MAM, meprin, A5 protein and receptor protein tyrosine phosphatase mu | NPM, nucleophosmin | mTOR, mammalian target of rapamycin | NIPA, nuclear interacting partner of ALK | RPTP, receptor protein tyrosine phosphatase | inflammatory myofibroblastic tumour (IMT) | DLBCL, diffuse large B-cell lymphoma | FOXO3a, forkhead box O 3a | NF-κB, nuclear factor κB | Shp1, SH2 domain-containing phosphatase 1 | RANBP2, Ran-binding protein 2 | ALCL, anaplastic large cell lymphoma | Dpp, decapentaplegic | FRS2, fibroblast growth factor receptor substrate 2 | LDLa, low-density lipoprotein class A | EGFR, epidermal growth factor receptor | SEC31L1, SEC31 homologue A | GIST, gastrointestinal stromal tumour | RTK, receptor tyrosine kinase | SH2, Src homology 2 | TFG, TRK-fused gene | ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | midkine | CLTC, clathrin heavy chain | anaplastic large cell lymphoma (ALCL) | MAPK, mitogen-activated protein kinase | Hen-1, hesitation-1 | MEK, MAPK | PI3K, phosphoinositide 3-kinase | HEK, human embryonic kidney | SCD-2, suppressor of constitutive dauer 2 | Review | EBPβ, CCAAT | CARS, cysteinyl-tRNA synthetase | JNK, c-Jun N-terminal kinase | ERK kinase | Grb2, growthfactor-receptor-bound protein 2 | SCC, squamous cell carcinoma | EML4, echinoderm microtubule-associated protein like 4 | SHH, sonic hedghog | BCR-Abl, breakpoint cluster region-Abl | IR, insulin receptor | ALO17, ALK lymphoma oligomerization partner on chromosome 17 | enhancer-binding protein β | PLCγ, phospholipase Cγ | NSCLC, non-small cell lung cancer | UCN-01, unco-ordinated 1 | non-small cell lung cancer (NSLCL) | Cdc42, cell division cycle 42 | STAT, signal transducer and activator of transcription | anaplastic lymphoma kinase (ALK) | DRG, dorsal root ganglia | MSN, moesin | dALK, Drosophila ALK | IL-3, interleukin-3 | CNS, central nervous system | JAK, Janus kinase | CML, chronic myeloid leukaemia | Jeb, jelly belly | IMT, inflammatory myofibroblastic tumour
Journal Article
Details
Digital rights
Loading RightsJournal of medicinal chemistry, ISSN 0022-2623, 04/2016, Volume 59, Issue 7, pp. 3392 - 3408
Lung Neoplasms - drug therapy | Rats, Wistar | Humans | Lung Neoplasms - metabolism | Receptor, trkA - antagonists & inhibitors | Crystallography, X-Ray | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Benzamides - administration & dosage | Protein Kinase Inhibitors - chemistry | Anaplastic Lymphoma Kinase | Microsomes, Liver - drug effects | Receptor, trkB - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Tumor Cells, Cultured | Benzamides - chemistry | Proto-Oncogene Proteins - antagonists & inhibitors | Indazoles - chemistry | Administration, Oral | Crystallization | Receptor, trkC - antagonists & inhibitors | Rats | Antineoplastic Agents - chemistry | Mice, SCID | Blood-Brain Barrier - drug effects | Drug Discovery | Blotting, Western | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Mice, Nude | Cell Membrane Permeability - drug effects | Dogs | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details
Digital rights
Loading RightsEuropean journal of medicinal chemistry, ISSN 0223-5234, 05/2018, Volume 151, pp. 304 - 314
PROTAC | Anaplastic lymphoma kinase | Lymphoma | Lung cancer | Protein degrader | Protein Kinase Inhibitors - pharmacokinetics | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Male | Antineoplastic Agents - chemistry | Receptor Protein-Tyrosine Kinases - metabolism | Lymphoma - metabolism | Proteolysis - drug effects | Lymphoma - drug therapy | Protein Kinase Inhibitors - chemistry | Animals | Anaplastic Lymphoma Kinase | Signal Transduction - drug effects | Drug Design | Cell Line, Tumor | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Proteins | Medical colleges | Plasma physics | Proteolysis | Lymphomas | Drug discovery | Drug resistance | Lung cancer, Non-small cell | Drug approval | Index Medicus
Journal Article
Details
Digital rights
Loading RightsAnnals of oncology, ISSN 0923-7534, 11/2018, Volume 29, Issue 11, pp. 2214 - 2222
ALK-positive | Alectinib | CNS | NSCLC | Life Sciences & Biomedicine | Oncology | Science & Technology | Brain - diagnostic imaging | Tumor Burden - radiation effects | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Lung - diagnostic imaging | Anaplastic Lymphoma Kinase - genetics | Young Adult | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Piperidines - pharmacology | Aged, 80 and over | Adult | Female | Lung - radiation effects | Lung Neoplasms - genetics | Chemoradiotherapy - methods | Crizotinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Brain Neoplasms - genetics | Treatment Outcome | Brain - radiation effects | Lung Neoplasms - therapy | Disease Progression | Brain - drug effects | Magnetic Resonance Imaging | Carcinoma, Non-Small-Cell Lung - therapy | Tumor Burden - drug effects | Piperidines - therapeutic use | Crizotinib - pharmacology | Lung - drug effects | Brain Neoplasms - therapy | Lung Neoplasms - diagnostic imaging | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carbazoles - pharmacology | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Index Medicus | Original articles | alectinib
Journal Article
Details
Digital rights
Loading RightsBlood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5496 - 5504
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Lymphoma, Large-Cell, Anaplastic - immunology | Recurrence | Prognosis | Follow-Up Studies | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Male | North America | Protein-Tyrosine Kinases - immunology | Anaplastic Lymphoma Kinase | Skin Neoplasms - mortality | Adult | Female | Retrospective Studies | Skin Neoplasms - pathology | Diagnosis, Differential | Lymphoma, Large-Cell, Anaplastic - therapy | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Europe | Immunophenotyping | Treatment Outcome | International Cooperation | Receptor Protein-Tyrosine Kinases | Lymphoma, Large-Cell, Anaplastic - mortality | Asia | Lymphoma, T-Cell, Peripheral - pathology | Survival Analysis | Lymphoma, Large-Cell, Anaplastic - pathology | Lymphoma, T-Cell, Peripheral - therapy | Lymphoma, T-Cell, Peripheral - mortality | Lymphoma, T-Cell, Peripheral - immunology | Index Medicus | Abridged Index Medicus
Journal Article
Details
Digital rights
Loading RightsBritish journal of haematology, ISSN 0007-1048, 06/2019, Volume 185, Issue 6, pp. 1043 - 1054
Children's Oncology Group | anaplastic large cell lymphoma | anaplastic lymphoma kinase inhibitors | European Inter‐Group for Childhood non‐Hodgkin Lymphoma | anaplastic lymphoma kinase | European Inter-Group for Childhood non-Hodgkin Lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Lymphoma, Large-Cell, Anaplastic - therapy | Prognosis | Humans | Translational Medical Research | Treatment Outcome | Combined Modality Therapy | Lymphoma, Large-Cell, Anaplastic - etiology | Molecular Targeted Therapy | Biomarkers, Tumor | Anaplastic Lymphoma Kinase - genetics | Lymphoma, Large-Cell, Anaplastic - diagnosis | Protein Kinase Inhibitors - therapeutic use | Anaplastic Lymphoma Kinase - metabolism | Disease Management | Protein Kinase Inhibitors - pharmacology | Child | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Lymphoma, Large-Cell, Anaplastic - metabolism | Aluminum compounds | Pediatrics | Lymphomas | T cells | Translocation | Medical research | Young adults | Therapeutic applications | Clinical trials | Lymphocytes T | Biology | Kinases | Lymphoma | Survival | Proteins | Chemotherapy | Lymphocytes | Anaplastic large-cell lymphoma | Fusion protein | Protein-tyrosine kinase | Hodgkin's disease | Index Medicus
Journal Article
Details
Digital rights
Loading Rights